CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that has become a key research peptide in the field of endocrine and growth hormone studies. This article examines its mechanisms, research applications, and the importance of sourcing from reliable peptides raw material manufacturers.
What Is CJC-1295?
CJC-1295 is a modified GHRH analog containing a Drug Affinity Complex (DAC) technology that binds the peptide to serum albumin, extending its half-life from minutes to several days. A single CJC-1295 dose produced 2- to 10-fold GH elevation persisting 6 or more days, with IGF-1 rising 1.5- to 3-fold.
Mechanism of Action
CJC-1295 activates the GH/IGF-1 axis by acting as a growth hormone-releasing hormone receptor agonist. Prolonged stimulation results in sustained secretion of growth hormone and insulin-like growth factor I. Subcutaneous administration results in sustained hormonal effects.
2026 Research Findings
– Muscle Research : CJC-1295 combined with ipamorelin showed significantly improved maximum tetanic tension in murine models with glucocorticoid-induced muscle loss, though these findings are limited to animal studies.
– Clinical Status : CJC-1295 remains investigational, with Phase 2 trials discontinued and no FDA approval.
Research Applications
CJC-1295 is utilized in laboratory settings for growth hormone regulation and pulsatility studies, muscle preservation and recovery research, metabolic and body composition studies, and aging and gerontology research.
Regulatory Status
As of April 2026, CJC-1295 is on the FDA 503A Category 2 bulk substances list, meaning it cannot be legally compounded under Section 503A pending further FDA review. Neither CJC-1295 nor its combinations are FDA-approved for any indication.
Sourcing Considerations
When sourcing CJC-1295 from peptide raw material suppliers, verify:
– HPLC Purity : ≥98% with batch-specific COA.
– Mass Confirmation : Verification of the correct molecular weight (approximately 3,647 Da).
– Endotoxin Testing : Essential for in-vivo studies.
– DAC Confirmation : Evidence of the Drug Affinity Complex modification.
Product Disclaimer & Terms of Use
IMPORTANT NOTICE: FOR RESEARCH USE ONLY (RUO)
This product is intended exclusively for laboratory research and scientific development purposes. It is NOT a drug, food, medical device, cosmetic, or diagnostic product.